Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
Improving the Prognoses of Multiple Myeloma
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
HF Management for Patients with Comorbid Conditions
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
FINE-HEART Pooled Analysis
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?